Avexegen Therapeutics is an early stage development company working on novel and revolutionary therapies for the $10 Billion GI Market. Our lead drug candidate, Neuregulin-4 (NRG-4), offers a completely new approach to directly heal damaged and inflamed gut tissue in patients with Crohn’s Disease and ulcerative colitis, as well as in premature infants with necrotizing enterocolitis (NEC)
10210 Campus Point Dr Ste 150
San Diego CA 92121
© 2015 | Avexegen Therapeutics, Inc.
In the News:
Avexegen Therapeutics Receives NIH Grant to Develop Treatments for Inflammatory Bowel Disease
SAN FRANCISCO, CA (PRWEB) OCTOBER 27, 2016
Avexegen Therapeutics Inc. (the Company), an innovative biotechnology company developing novel therapies for gastrointestinal disorders, today announced that it has received an award of $225,000 under the National Institutes
of Health’s Small Business Innovation Research Program (SBIR) for the development of therapies for inflammatory bowel disease including Crohn’s disease and ulcerative colitis.
More than 1.4 million people in North America suffer chronically with Crohn’s disease and ulcerative colitis, and for many the diseases are not well controlled with currently available therapies. Avexegen will use the NIH grant to advance the development of their lead drug candidate, Neuregulin-4 (NRG-4) by exploring different routes of drug delivery. Multiple preclinical proof-of-concept studies have revealed that NRG-4 has direct biological effects, simultaneously suppressing pro-inflammatory cytokines while driving the healing of damaged and inflamed epithelial tissue. “We believe that NRG-4, with its unique dual mode of action, has the potential to be a first-in-class therapy
that may further improve patient care and long term outcomes.” said Artin Asadourian, CEO of Avexegen Therapeutics.